Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Stroke Prevention Effects Confirmed in PIII Study of Pradaxa in Asia: BI Japan
June 17, 2013
- Daiichi Sankyo, JICA Start Technical Cooperation on MR Vaccine Production in Vietnam
June 17, 2013
- Sanofi Ends Development on Iniparib, Otamixaban
June 14, 2013
- ARBs Still Best Sellers in FY2012 Sales Ranking, Januvia Ranks in Top 10 after only 3 Years of Launch
June 14, 2013
- Nippon Shinyaku’s Licensee Taejoon Pharm Launches Gaslon N-OD Tablets in South Korea
June 14, 2013
- AbbVie, Meiji Seika Pharma Start PIII of Fluvoxamine for Pediatric OCD
June 14, 2013
- SGLT-2 Inhibitors Being Submitted for Marketing Authorization; First of 6 APIs Should Debut Next Spring
June 14, 2013
- Daiichi Sankyo Launches Osteoporosis Treatment Pralia
June 13, 2013
- Domestic Sales of OTC Drugs Expected to Reach 607.2 Billion Yen in 2013: Fuji-Keizai
June 13, 2013
- DSP, Shionogi Launch Avapro, Irbetan Tablets 200 mg
June 13, 2013
- Kyorin Launches Pentasa Suppositories
June 12, 2013
- Lenvatinib Add-on Therapy Improves PFS in Melanoma Patients: Eisai
June 12, 2013
- Nearly All Major Drug Makers Introduce Systems to Keep Workers over 60
June 12, 2013
- 6 Antipsychotics in PIII Studies; Flurry of NDA Filings Expected in 2015
June 12, 2013
- Pfizer Japan, Takeda Launch Enbrel New Pen Preparation
June 12, 2013
- Otsuka Chosen by METI as Model Enterprise for Efforts to Ensure Stable Drug Supplies During Emergencies
June 11, 2013
- R&D Operations Start for Diagnostic Products: Alfresa Pharma
June 11, 2013
- Announcement: Sales Force Effectiveness Japan 2013 to Be Held on July 16, 17
June 11, 2013
- Ethical, OTC Drug Sales Up 1.3% and 9.5%: Crecon Report
June 10, 2013
- Bayer to File Eylea for mCNV in Japan Later This Year
June 10, 2013
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…